N-(4-甲氧基苄基)氨基乙醛二甲基缩醛 | 54879-77-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-(4-甲氧基苄基)氨基乙醛二甲基缩醛
• 英文名称: 2-(4-methoxybenzylamino)acetaldehyde dimethyl acetal
• 英文别名: N-(4-methoxybenzyl)aminoacetaldehyde dimethyl acetal；2,2-Dimethoxy-N-(4-methoxybenzyl)ethanamine；2,2-dimethoxy-N-[(4-methoxyphenyl)methyl]ethanamine
• CAS: 54879-77-5
• 化学式: C₁₂H₁₉NO₃
• mdl: MFCD12148379
• 分子量: 225.288
• InChiKey: OPGMXQALDADLBH-UHFFFAOYSA-N

物化性质

• 沸点：
  301.2±32.0 °C(Predicted)
• 密度：
  1.034±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  16
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  39.7
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2922299090

反应信息

• 作为反应物：
  描述：

  N-(4-甲氧基苄基)氨基乙醛二甲基缩醛 在 盐酸 、 三溴化硼 作用下， 以 乙醇 、 二氯甲烷 、 水 为溶剂， 反应 3.5h， 生成 1-(4-羟基苄基)咪唑-2-硫醇
  参考文献：
  名称：

  Multisubstrate inhibitors of dopamine .beta.-hydroxylase. 2. Structure-activity relationships at the phenethylamine binding site

  摘要：

  1-Aralkylimidazole-2-thiones have been shown to be potent multisubstrate inhibitors of dopamine beta-hydroxylase (DBH; EC 1.14.17.1). In the present study, a series of 1-benzylimidazole-2-thiones was prepared to explore the effects of substitution in the benzyl ring on the inhibition of DBH. A detailed structure-activity relationship for in vitro activity was discovered and this was shown by a modified Hansch analysis to correlate (r = 0.91) with four key structural features of the benzyl ring: the presence of a hydroxyl at the 4-position, molar refractivity at the 3-, 4-, and 5-positions, inductive effects of the substituents at the 3-, 4-, and 5-positions, and pi-electron density. The affinity (Kis) of eight substituted inhibitors for DBH was shown to correlate (r = 0.75) with the affinity (KD) of comparably substituted tyramines for the ternary DBH-oxygen-tyramine complex. This correlate is used to support the hypothesis that binding of inhibitor to DBH occurs in a fashion that mimics the binding of tyramine substrates. The most potent inhibitors were selected for study in vivo in the spontaneously hypertensive rat model of hypertension. The changes in vascular dopamine and norepinephrine levels that resulted from oral administration of the inhibitors corresponded to the observed reduction in mean arterial blood pressure. A divergence between in vitro potency and in vivo efficacy upon oral dosing was noted and is suggested to result from an in vivo metabolic conjugation of the phenolic group of inhibitor.

  DOI：

  10.1021/jm00386a008
• 作为产物：
  描述：

  (E)-N-(4-甲氧基亚苄基)-2,2-二甲氧基乙胺 在 sodium tetrahydroborate 作用下， 以 乙醇 为溶剂， 反应 24.0h， 生成 N-(4-甲氧基苄基)氨基乙醛二甲基缩醛
  参考文献：
  名称：

  Multisubstrate inhibitors of dopamine .beta.-hydroxylase. 2. Structure-activity relationships at the phenethylamine binding site

  摘要：

  1-Aralkylimidazole-2-thiones have been shown to be potent multisubstrate inhibitors of dopamine beta-hydroxylase (DBH; EC 1.14.17.1). In the present study, a series of 1-benzylimidazole-2-thiones was prepared to explore the effects of substitution in the benzyl ring on the inhibition of DBH. A detailed structure-activity relationship for in vitro activity was discovered and this was shown by a modified Hansch analysis to correlate (r = 0.91) with four key structural features of the benzyl ring: the presence of a hydroxyl at the 4-position, molar refractivity at the 3-, 4-, and 5-positions, inductive effects of the substituents at the 3-, 4-, and 5-positions, and pi-electron density. The affinity (Kis) of eight substituted inhibitors for DBH was shown to correlate (r = 0.75) with the affinity (KD) of comparably substituted tyramines for the ternary DBH-oxygen-tyramine complex. This correlate is used to support the hypothesis that binding of inhibitor to DBH occurs in a fashion that mimics the binding of tyramine substrates. The most potent inhibitors were selected for study in vivo in the spontaneously hypertensive rat model of hypertension. The changes in vascular dopamine and norepinephrine levels that resulted from oral administration of the inhibitors corresponded to the observed reduction in mean arterial blood pressure. A divergence between in vitro potency and in vivo efficacy upon oral dosing was noted and is suggested to result from an in vivo metabolic conjugation of the phenolic group of inhibitor.

  DOI：

  10.1021/jm00386a008

文献信息

• Diversity-oriented synthesis of novel polycyclic scaffolds using polymer-bound reagents
  作者：Domingo García-Cuadrado、Sofia Barluenga、Nicolas Winssinger

  DOI：10.1039/b807869f

  日期：——

  A concise sequence utilizing a Petasis three component reaction followed by a tandem aza-Cope–Mannich cyclization afforded novel polycyclic heterocycles in good yield; alternative iminium cyclization based on a Pictet–Spengler reaction or aminal formation led to divergent pathways affording skeletal diversity.

  通过Petasis三组分反应与随后的aza-Cope-Mannich串联环化反应，简洁地合成了产率良好的新型多环杂环化合物；基于Pictet-Spengler反应或氨基醛缩合的亚胺环化提供了不同的途径，导致了骨架多样性。
• Design, Synthesis, and Biological Evaluation of Imidazopyrazinone Derivatives as Antagonists of <scp>Inhibitor of Apoptosis Proteins</scp> (IAPs)
  作者：Jisook Kim、Inhwan Bae、Jiyoung Song、Younghoon Kim、Younggil Ahn、Hyun‐Ju Park、Ha Hyung Kim、Dae Kyong Kim

  DOI：10.1002/bkcs.12271

  日期：2021.6

  proteins are overexpressed in many cancers and implicated in tumor growth, so the development of antagonist that disrupts with the binding of IAP to their partner protein is a promising therapeutic strategy. In an effort to increase cellular activity and improve favorable drug-like properties, we newly designed and synthesized monovalent analogues based on imidazopyrazinone structure of 9. Optimization

  凋亡抑制剂 (IAP) 蛋白在许多癌症中过度表达并与肿瘤生长有关，因此开发可破坏 IAP 与其伙伴蛋白结合的拮抗剂是一种很有前景的治疗策略。为了增加细胞活性并改善有利的类药物特性，我们新设计并合成了基于9咪唑并吡嗪酮结构的单价类似物。细胞效力的优化导致17的鉴定，这表 明亚微摩尔活性 (GI 50 = 234 nM) 和 Caspase-3 激活（6.3 倍）在 MDA-MB-231 乳腺癌细胞中增加。这些发现清楚地表明了17 作为开发有效抗癌治疗的有前途的单价拮抗剂。
• Synthesis of tetrahydroisoquinolines through TiCl4-mediated cyclization and Et3SiH reduction
  作者：Zeyu Shi、Qiong Xiao、Dali Yin

  DOI：10.1016/j.cclet.2019.09.023

  日期：2020.3

  Abstract A versatile and efficient telescoped reaction sequence for the synthesis of tetrahydroisoquinolines (THIQs) is reported that uses TiCl4 to promote cyclization of a benzylaminoacetal derivative and Et3SiH for reduction of the intermediate 4-hydroxy-THIQ. This method is complimentary to the classical Pomeranz-Fritsch and related reactions since it tolerates electron-withdrawing substituents

  摘要报道了一种通用且有效的伸缩反应序列，用于合成四氢异喹啉（THIQs），该序列使用TiCl4促进苄氨基缩醛衍生物的环化反应，并使用Et3SiH还原中间体4-羟基-THIQ。此方法是对经典Pomeranz-Fritsch和相关反应的补充，因为它可以耐受吸电子取代基并允许使用8位取代的THIQ。
• [EN] CYCLIC AMINE DERIVATIVES HAVING BETA2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY<br/>[FR] DÉRIVÉS D'AMINE CYCLIQUE AYANT UNE ACTIVITÉ AGONISTE DE RÉCEPTEUR ADRÉNERGIQUE BÊTA-2 ET ANTAGONISTE DE RÉCEPTEUR MUSCARINIQUE
  申请人：ASTRAZENECA AB

  公开号：WO2011048409A1

  公开（公告）日：2011-04-28

  Compounds of formula (I) having activities at muscarinic and β2-receptors (MABAs) for use in therapy.

  具有在毒蕈碱受体和β2受体（MABAs）上活性的化合物（I）的公式，用于治疗。
• Synthesis of 1,2-Dihydroisoquinolines by a Modified Pomeranz–Fritsch Cyclization
  作者：Xiang Ji、Zheng Huang、Jean-Philip Lumb

  DOI：10.1021/acs.joc.9b02987

  日期：2020.1.17

  Isoquinolines (IQs) and their derivatives are present in many natural products and biologically active small molecules. Herein, we report a modified procedure for the classical Pomeranz-Fritsch protocol, which expands the scope of 1,2-dihydroisoquinoline (DHIQ) products. 1,2-DHIQs are an attractive branch point for the synthesis of IQs, but because of their innate reactivity, they have remained difficult

  异喹啉（IQ）及其衍生物存在于许多天然产物和具有生物活性的小分子中。在此，我们报告了经典Pomeranz-Fritsch协议的修改程序，该程序扩展了1,2-二氢异喹啉（DHIQ）产品的范围。1,2-DHIQ是合成IQ的一个有吸引力的分支点，但是由于其先天的反应性，它们仍然很难制备。我们证明了结合三甲基甲硅烷基三氟甲磺酸酯（TMSOTf）和胺碱的Fujioka / Kita条件，可以在足够温和的条件下活化Pomeranz-Fritsch环化所需的二甲基缩醛，以制备各种1,2-DHIQ产品。我们还通过进一步功能化为还原的四氢异喹啉（THIQ）或完全芳香化的IQ天然产品来证明这些DHIQ的合成价值。